Context: Starting face-to-face education while the COVID-19 pandemic was ongoing was a risk for public health. Determining teachers' initial reactions to public health practices during this high-risk period may contribute to the redesign of public health and school nursing policies.
Objective: The aim of this research is to examine the relationship between primary school teachers' COVID-19 fear levels and COVID-19 vaccine attitudes.
Design: The research has a descriptive correlational design. The data were obtained from teachers working in primary schools (n = 430). Simple random sampling method was used in the data collection process. Data were obtained with the Scale of Attitudes Towards COVID-19 Vaccine and Fear of COVID-19 Scale.
Results: In the study, 50.5% of teachers reported that they were afraid of catching COVID-19, 41.9% said their risk of catching COVID-19 was "high," and 87.7% reported that they voluntarily got the COVID-19 vaccine. Of the teachers, 4.6% (n = 20) stated that they regretted getting vaccinated. A positive and significant relationship was found between teachers' Fear of COVID-19 Scale and COVID-19 Vaccine Attitude Scale scores (r = 0.133, p < 0.001).
Conclusions: During the pandemic, it was observed that teachers' fear level of COVID-19 increased with the start of face-to-face education. In addition, it is seen that teachers started to have doubts about some public health practices. This may indicate that public health nurses should take a more active role in school health practices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700933 | PMC |
http://dx.doi.org/10.1111/phn.13469 | DOI Listing |
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFCurr Vasc Pharmacol
January 2025
Department of Urology, People's Hospital of Longhua, Shenzhen, Guangdong, 518109, China.
Aims: This study aims to conduct a bibliometric and visual analysis of published studies on myocarditis and coronavirus disease 2019 (COVID-19) vaccines.
Background: The widespread epidemic of COVID-19 has caused millions of deaths and profoundly affected the global medical landscape. Studies on COVID-19 vaccination and related myocarditis have also increased significantly.
Rev Panam Salud Publica
January 2025
Organización Panamericana de la Salud Washington D. C. Estados Unidos Organización Panamericana de la Salud, Washington D. C., Estados Unidos.
Objective: To describe the functioning of the surveillance system for adverse events following immunization (AEFI) in Colombia using the evaluation tools proposed by the World Health Organization (WHO).
Method: Descriptive study of the performance of the AEFI surveillance system for COVID-19 vaccines between 17 February 2021 and 30 September 2023. WHO indicators for structure, process, and results were adapted.
Indian J Clin Biochem
January 2025
Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India.
The first two vaccines administered in the COVID-19 vaccination campaign of India were Covaxin (BBV152) and Covishield (ChAdOx1-nCoV-19). In this study, we evaluate the longevity and sustainability of the humoral immune response after vaccination and various factors influencing it. An observational study was conducted in individuals who received both doses of Covaxin or Covishield vaccine, and their blood samples were analyzed for total-antiRBD-SARS-CoV-2 antibodies.
View Article and Find Full Text PDFInfect Drug Resist
January 2025
Department of Public Health, School of Allied Health Sciences, Kampala International University, Western Campus, Uganda.
Introduction: Coronavirus Disease 19 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and Human Immunodeficiency Virus (HIV) are significant 21st-century pandemics with distinct virological and clinical characteristics. COVID-19 primarily presents as an acute respiratory illness, while HIV leads to chronic immune suppression. Understanding their differences can enhance public health strategies and treatment approaches.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!